Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Comparative Hypertensive Trials Preferred Endpoint Is Systolic BP, Cmte Says

Executive Summary

The primary efficacy endpoint in comparative antihypertensive trials should shift from diastolic blood pressure measured at trough levels to systolic blood pressure at trough, FDA's Cardiovascular & Renal Drugs Advisory Committee member Steven Nissen, MD, suggested July 18
Advertisement

Related Content

Atacand Label May Note 2 mm Hg BP Reduction Over Cozaar, Cmte. Says
Atacand Label May Note 2 mm Hg BP Reduction Over Cozaar, Cmte. Says
King Altace sNDA Submitted For Five Indications; 4th Quarter Sales Grew 46%
Advertisement
UsernamePublicRestriction

Register

PS040220

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel